Diko Kazandjian: IsaVRD more is better

Dickran (Diko) Kazandjian, Professor of Medicine at the Sylvester Comprehensive Cancer Center and Board Member of OncoDaily, shared on X/Twitter:

”IsaVRD (Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone (VRD)). More is better. For transplant-eligible patients with newly diagnosed multiple myeloma who are under 80 years old.”